- AU$18.25m
- AU$15.94m
- AU$11.93m
- 62
- 47
- 82
- 68
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.24 | ||
| Price to Tang. Book | 3.24 | ||
| Price to Free Cashflow | 44.61 | ||
| Price to Sales | 1.26 | ||
| EV to EBITDA | 28.36 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.13% | ||
| Return on Equity | -12.21% | ||
| Operating Margin | 0.07% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 5.29 | 3.85 | 4.79 | 5.1 | 11.93 | n/a | n/a | 28.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto(estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Directors
- Ross Dobinson NEC
- Michael Kotsanis CEO
- Joanna Johnson CFO
- Felicia Colagrande OTH
- Mark Hyman OTH
- Charles O'Sullivan OTH
- Geoffrey Brooke NID
- Don Brumley NID
- Timothy Oldham NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 19th, 1998
- Public Since
- September 29th, 2004
- No. of Shareholders
- 4,797
- No. of Employees
- 43
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 289,630,985
- Address
- 103-113 Stanley St, West Melbourne, MELBOURNE, 3003
- Web
- https://www.acrux.com.au/
- Phone
- +61 383790100
- Auditors
- Pitcher Partners
Upcoming Events for ACR
Similar to ACR
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
Biome Australia
Australian Stock Exchange - SEATS
FAQ
What is the Acrux share price?
As of Today at 19:00 UTC, shares in Acrux are trading at AU$0.06. This share price information is delayed by 15 minutes.
How has the Acrux share price performed this year?
Shares in Acrux last closed at AU$0.06 and the price had moved by +16.67% over the past 365 days. In terms of relative price strength the Acrux share price has outperformed the ASX All Ordinaries Index by +8.67% over the past year.
What are the analyst and broker recommendations for Acrux?
The overall consensus recommendation for Acrux is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Acrux dividend yield?
Acrux does not currently pay a dividend.
Does Acrux pay a dividend?
Acrux does not currently pay a dividend.
When does Acrux next pay dividends?
Acrux does not currently pay a dividend.
How do I buy Acrux shares?
To buy shares in Acrux you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Acrux?
As of the previous close price of AU$0.06, shares in Acrux had a market capitalisation of AU$18.25m.
Where are Acrux shares listed?
Here are the trading details for Acrux:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ACR
What kind of share is Acrux?
Based on an overall assessment of its quality, value and momentum Acrux is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Acrux share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Acrux share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acrux. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +30.92%.
As of the last closing price of AU$0.06, shares in Acrux were trading +27.64% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Acrux PE Ratio?
The Acrux PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Acrux?
Acrux's management team is headed by:
- Ross Dobinson - NEC
- Michael Kotsanis - CEO
- Joanna Johnson - CFO
- Felicia Colagrande - OTH
- Mark Hyman - OTH
- Charles O'Sullivan - OTH
- Geoffrey Brooke - NID
- Don Brumley - NID
- Timothy Oldham - NID